SCHEMBL3129606

SCHEMBL3129606

Cc1ncsc1S(N)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
PKM P14618 1/20 0.42
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
CA2 P00918 12/20 0.34
CA1 P00915 11/20 0.34
CA9 Q16790 10/20 0.34
CA12 O43570 8/20 0.34
CA5A P35218 5/20 0.33
CA5B Q9Y2D0 5/20 0.33
CA7 P43166 3/20 0.33
CA6 P23280 2/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30276878 0.85 KDM4E (0.38) KDM4EPKMALDH1A1MEN1LMNA
SCHEMBL21918985 0.82 KDM4E (0.42) KDM4EPKMALDH1A1MEN1LMNA
SCHEMBL3989665 0.80 KDM4E (0.41) KDM4EPKMALDH1A1MEN1LMNA
SCHEMBL2654567 0.80 KDM4E (0.45) KDM4EPKMALDH1A1MEN1LMNA
SCHEMBL14612384 0.80 KDM4E (0.41) KDM4EPKMALDH1A1MEN1LMNA
Hydrochloric Acid SCHEMBL27764055 0.78 KDM4E (0.44) KDM4EPKMALDH1A1MEN1LMNA
SCHEMBL31664536 0.77 KDM4E (0.38) KDM4EPKMALDH1A1MEN1LMNA
SCHEMBL415794 0.74 KDM4E (0.36) KDM4EPKMALDH1A1MEN1LMNA
SCHEMBL15653253 0.72 KDM4E (0.39) KDM4EPKM
SCHEMBL539978 0.70 KDM4E (0.33) KDM4EPKMALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109563-A1 SPIRO-HYDANTOIN DERIVATIVE EXHIBITING ADAMTS-4 INHIBITORY ACTIVITY, AND USE THEREOF 서울대학교병원 2025-05-30 WO claimed
CN-109054648-A Serosity combination for chemically mechanical polishing LTCAM有限公司 2018-12-21 CN claimed
EP-4580601-A1 PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS Assembly Biosciences, Inc. (US) 2025-07-09 EP disclosed
WO-2025046456-A1 A CRYSTALLINE FORM OF 2-(3-(2,,5'-DIFLUORO-[1,1'-BIPHENYL]-4-YL)-2-OXOTETRAHYDROPYRIMIDIN-1(2H)-YL)-4-METHYLTHIAZOLE-5-SULFONAMIDE ASSEMBLY BIOSCIENCES, INC. (US) 2025-03-06 WO disclosed
WO-2025046457-A1 A CRYSTALLINE FORM OF 2-(3-(2,,5'-DIFLUORO-[1,1'-BIPHENYL]-4-YL)-2-OXOTETRAHYDROPYRIMIDIN-1(2H)-YL)-4-METHYLTHIAZOLE-5-SULFONAMIDE ASSEMBLY BIOSCIENCES, INC. (US) 2025-03-06 WO disclosed
WO-2024047508-A1 PHARMACEUTICAL COMPOSITIONS FOR HERPES VIRUS ASSEMBLY BIOSCIENCES, INC. (US) 2024-03-07 WO disclosed
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
WO-2010045580-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS EXELIXIS, INC. (US) 2010-04-22 WO disclosed
EP-0847391-B1 AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2001-12-19 EP disclosed
US-6100258-A 6-(N-(5-BROMO-2-(2-METHYLPROP-2-EN-1-YLOXY)BENZYL)-N -ETHYLAMINO)-PYRIDAZIN-3-YLCARBOXYLIC ACID, AND OTHER 3,6-DISUBSTITUTED PYRIDAZINE DERIVATIVES OF SPECIFIED FORMULA; RELIEVING PAIN ZENECA LIMITED (GB) 2000-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 KDM4E 2480/4885PKM 527/4885ALDH1A1 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.